Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian equity markets remain firm
Fri, 19 Jul 01:30 pm

Indian equity markets continued to trade in the positive territory during the post noon trading session. Among the sectoral indices, the stocks from the IT sector and auto sector were leading among gainers, while capital goods and power stocks were the leading losers.

BSE-Sensex is up by 105 points and NSE-Nifty is trading up by 16 points. While BSE Mid Cap is trading down by 0.2%, BSE Small Cap index is trading up by 0.1%. The rupee is trading at 59.73 to the US dollar.

Majority of the automobile stocks are trading in the green with Force Motors and Hero MotoCorp being the biggest gainers. As per a leading financial daily, Ashok Leyland is expanding its portfolio in the defence segment by launching its Super Stallion range of vehicles in the domestic and overseas markets. The Super Stallion is a significantly bigger platform. Typically, Stallion is 230 HP, and Super Stallion is 360-400 HP. Ashok Leyland has established a new company called Ashok Leyland Defence System Ltd to foray into the defence sector. The company has a partnership for gun mounted systems and also has a platform for short missile systems. As per the company, it is the largest private supplier to the armed forces in India with its Ashok Leyland Stallion. Ashok Leyland stock is trading marginally down.

Indian pharma stocks are trading mixed with Aurobindo and Sun Pharma witnessing maximum selling pressure, while Orchid Chemicals and Piramal Enterprises are the top gainers. As per a financial daily, while Ranbaxy holds 180-days exclusivity on Diovan, it is awaiting approval from the USFDA (United States Food and Drug Administration) to launch the drug. However, Ranbaxy's delay in launch has been positive for the innovator Novartis. This is because, once Ranbaxy launches the drug, the innovator will witness sharp fall in its revenues of the said brand. Reportedly, the Swiss based company believes the generics for Diovan are not expected atleast till September 2013. This signifies that Ranbaxy's launch could further get delayed till the said time period. Ranbaxy was trading down by 1.2%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian equity markets remain firm". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.